Kidney and Metabolic Bone Diseases Vol.27 No.2(11)

Series Clinical Investigation
Title Study indicating improved kidney function and HDL-C, with administration of native vitamin D
Publish Date 2014/04
Author Takashi Kuwahara Department of Nephrology, Saiseikai Ibaraki Hospital
Author Sachiko Yamada Department of Nephrology, Saiseikai Ibaraki Hospital
Author Kensuke Nishiguchi Department of Nephrology, Saiseikai Ibaraki Hospital
Author Shouhei Soukawa Department of Nephrology, Saiseikai Ibaraki Hospital
Author Riiyan Wan Department of Nephrology, Saiseikai Ibaraki Hospital
[ Summary ] Individuals who work in medical institutions often have limited opportunities to be exposed to adequate levels of sunlight to generate innate levels of vitamin D. Subjects consisted of seven nursing home employees as well as nine nurses working in the Ibaraki Hospital. Mean subject age was 46.1 ± 7.1 years. Subjects were administered Panvitan ® at levels of 1g containing 200 IU of ergocalciferol over a period of three months. Native vitamin D3 (1,000 IU of cholecalciferol) was subsequently administered three times a week. Blood samples were obtained at time of each administration. Serum levels were 25OHVD (ng/ml) compared to levels of 19.5 before administration. Levels rose slightly to 21.9 with Panvitan administration, and up to 31.9 after D3 administration. Renal function, as reflected by eGFR (ml/min) levels was 71.0 at initiation of medication and rose to 75.8 after Panvitan administration. It subsequently rose to 93.5 with continued vitamin administration. Initial HDL-C (mg/dl) levels were 67.1, rising to 69.8. No changes were observed in LDL-C, TG, Ca or Pi values. These results confirm previous reports in which vitamin D was seen to reduce urinary protein levels, without causing adverse effects on kidney function in CKD patients, in addition to increased HDL-C and unchanged LDL-C levels. In conclusion, subjects with improved levels of 25OHVD exhibited improved kidney function and increased HDL-C levels.
back